FABP

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR

Cat.No.	Product Name	Information	Product Use Citations
S6622	BMS-309403	BMS309403 is a small-molecule FABP4 inhibitor with nM affinity (Kd=4 nM for FABP4) and >100-fold selectivity against FABP5 as well as the heart isoform FABP3.	Kidney Diseases, February 05, 2025, 75-89 Scientific Reports, August 20, 2025, 30552 Cell Death & Disease, April 11, 2022, 333
S9957	SBFI-26	SBFI-26 competitively inhibits the activities of FABP5 and FABP7.	World J Clin Oncol, 2024, 15(1):130-144
E4780	ART26.12	ART26.12 is an inhibitor of fatty acid-binding protein 5 (FABP5) that selectively binds to FABP5 over FABP3, FABP4, and FABP7, exhibiting antinociceptive properties. It alleviates oxaliplatin-induced pain through lipid modulation and cannabinoid receptor activation, with potential for preventing and treating oxaliplatin-induced peripheral neuropathy (OIPN).

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S6622

BMS-309403

BMS309403 is a small-molecule FABP4 inhibitor with nM affinity (Kd=4 nM for FABP4) and >100-fold selectivity against FABP5 as well as the heart isoform FABP3.

Kidney Diseases, February 05, 2025, 75-89

Scientific Reports, August 20, 2025, 30552

Cell Death & Disease, April 11, 2022, 333

S9957

SBFI-26

SBFI-26 competitively inhibits the activities of FABP5 and FABP7.

World J Clin Oncol, 2024, 15(1):130-144

E4780

ART26.12

ART26.12 is an inhibitor of fatty acid-binding protein 5 (FABP5) that selectively binds to FABP5 over FABP3, FABP4, and FABP7, exhibiting antinociceptive properties. It alleviates oxaliplatin-induced pain through lipid modulation and cannabinoid receptor activation, with potential for preventing and treating oxaliplatin-induced peripheral neuropathy (OIPN).